Reisa Sperling, M.D.
Professional Information
Professor of Neurology, Harvard Medical School
MD , Harvard Medical School,
Contact
Mailing Address
221 Longwood Avenue
Boston, MA 02115 USA
Biosketch
A. Personal Statement I am a Board Certified neurologist who has
B. Positions and Honors
been working in aging and Alzheimers disease (AD) research for 15 years. My work
has been focused on early diagnosis and treatment of AD, in particular, developing
neuroimaging markers, including functional and structural MRI and PET amyloid
imaging, for early detection of brain dysfunction and potential outcome markers
for clinical trials. I serve as the Director of the Center for Alzheimer
Research and Treatment at Brigham and Womens Hospital, and the Director of the
Neuroimaging Core at the Massachusetts Alzheimers Disease Research Center
(ADRC) at Massachusetts General Hospital. I also had the honor of chairing the
National Institute on Aging/Alzheimers Association Workgroup on Preclinical
AD, and currently lead a large NIA Program Project, the Harvard Aging Brain
Study, working to differentiate the earliest stages of preclinical AD from healthy
aging, and an R01 developing functional imaging measures to track progression
in Mild Cognitive Impairment. I have been actively working on the design and
execution of potential disease-modifying trials in Alzheimers disease for the
past 10 years. I am the Project Leader for the recently funded ADCS
Anti-Amyloid Treatment in Asymptomatic AD (the A4) trial, a 1000 subject
secondary prevention trial in clinically normal older individuals with evidence
of amyloid pathology.
Positions and Employment:
1991-1992 Intern, Internal Medicine, Brigham and
Womens Hospital, Harvard Medical School, Boston, MA
1992-1994 Resident in Neurology, Harvard Longwood
Neurology Training Program, Boston, MA
1994-1995 Chief Resident in Neurology, Harvard
Longwood Neurology Training Program, Boston, MA
1995-1997 Clinical Fellow in Dementia and
Behavioral Neurology, Harvard Medical School, Boston, MA
1997-2002Instructor in Neurology, Harvard Medical School
1997-1999 Clinical Investigator Training Program,
Harvard/MIT Health Sciences and Technology
1997- Associate Neurologist, Brigham
and Womens Hospital, Massachusetts General Hospital,
2002-2006 Assistant Professor of Neurology, Harvard
Medical School
2003- Director of Clinical Research, Memory
Disorders Unit, Brigham and Womens Hospital
2004- Director,
Neuroimaging Program, Massachusetts ADRC, Massachusetts General Hospital
2007- Associate Professor of Neurology, Harvard
Medical School
2008- Director, Center for Alzheimer Research
and Treatment, Brigham and Women's Hospital
Other
Experience and Professional Memberships:
2002-2007 Editorial Board, Alzheimers Disease and
Associated Disorders
2002- Steering Committee, Alzheimers
Disease Cooperative Study, National Institute on Aging
2003-2006 Chair, Medical-Scientific Advisory
Committee, Massachusetts Chapter, Alzheimers Association
2005- Steering Committee, Data and Publications,
Alzheimers Disease Neuroimaging Initiative
2007- Standing
Member; NIA-N Study Section; National Institutes on Aging
2008-2009 Co-Chair,
Alzheimers Imaging Consortium, Program Committee, ICAD
2009- American
Academy of Neurology Research Council
2010- Chair,
NIA/Alzheimers Association Working Group on Preclinical Alzheimers disease
Honors:
1987 Magna Cum Laude, Phi Beta Kappa,
Columbia University
1991 Cum Laude, Honors in Special
Field Neuroscience, Harvard Medical School
1998AAN Education and Research Foundation Clinical
Research Training Fellowship
1999 50th
Anniversary in Medicine Award, Harvard Medical School
2003 New Project in
Translational Neuroscience Award, Brigham Institute for the Neurosciences
2003 Paul Beeson Faculty Scholars in Aging
Award, American Federation for Aging Research
2006 Memory Ride Award, Investigator Initiated
Grant, Alzheimers Association
2007 Research Award in Geriatric Neurology,
American Academy of Neurology
2010 Simons Lecture Awardee, Alzheimers
Association
C. Selected Peer-reviewed Publications (selected from over 70 publications)
- Sperling
RA, Bates JC, Cocchiarella
AJ, Schacter D, Rosen B, Albert M.
Encoding novel face-name associations: A functional MRI study. Human
Brain Mapping 2001;14(2):129-139. - Sperling
R, Greve D, Dale A, Kiliany
R, Rosen R, Homes J, Rosas HD, Cocchiarella A, Firth P, Lange N, Routledge C,
Albert M. Functional MRI Detection of
pharmacologically induced memory impairment. PNAS 2002; 99(1):455-460. - Sperling
RA, Bates J, Chua E,
Cocchiarella A, Rentz D, Rosen B, Schacter DL, Albert MS. Functional MRI
studies of associative encoding in elderly controls and mild AD patients. JNNP 2003;74:44-50. - Dickerson
BC, Salat D, Bates J, Atiya M, Killiany R, Greve D, Dale AM, Stern CE, Blacker
D, Albert MS, Sperling RA. MRI measures
of medial temporal lobe function and structure in questionable Alzheimers
disease. Annals of Neurology, 2004;
56(1):27-35. - Dickerson, BC, Salat D, Greve
D, Chua E, Rand-Giovannetti E, Rentz D, Betram L, Mullin K, Tanzi R, Blacker D,
Albert M, Sperling R. Increased
hippocampal activation in mild cognitive impairment compared to normal aging
and AD. Neurology 2005;65:404-411. - Rand-Giovannetti
E, Chua A, Driscoll A, Schacter D, Albert M, Sperling R. Hippocampus and neocortical activation during
repetitive encoding in older persons. Neurobiology
of Aging 2006; 27(1):173-182. - Rentz DM, Sardinha L, Huh T, Daffner K,
and Sperling RA. IQ-based Norms for Highly Intelligent
Adults. The Clinical Neuropsychologist 2006; 20(4):637-48. - Celone
KA, Calhoun VD, Dickerson B, Atri A, Chua EF, Miller S, DePeau K, Rentz DM,
Selkoe D, Blacker D, Albert MS, Sperling RA. Alterations in memory
networks in mild cognitive impairment and Alzheimers disease: An independent component analysis J Neuroscience 2006;
26 (40):10222-31. - Chappell, AS, Gonzales, Williams, J, Witte, MM,
Mohs, RC, Sperling, RA. AMPA
potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007; 68 1008-1012. - Diamond EL, Miller S, Dickerson BC, Atri A, DePeau K,
Fenstermacher E, Pihlajamki M, Celone K,
Salisbury S, Gregas M, Rentz D, Sperling RA. Relationship of fMRI
Activation to Clinical Trial Memory Measures in Alzheimer's Disease. Neurology 2007;69(13):1331-41. - Miller
SL, Celone K, DePeau K, Diamond E, Dickerson BC, Rentz D, Pihlajamki M, Sperling RA. Age-related
memory impairment associated with loss of parietal deactivation but preserved
hippocampal activation. Proceedings of
the National Academy of Sciences 2008;105(6):2181-6. PMCID: PMC2538895. - Buckner R, Sepulcre
J, Talukdar T, Krienen F, Liu H, Hedden T, Andrews-Hanna J, Sperling R, Johnson K. Cortical Hubs Revealed
by Intrinsic Functional Connectivity: J
Neuroscience 2009; 29(6):1860-73. PMC2750039 - Sperling RA, LaViolette PS, OKeefe K, et al. Amyloid Deposition is Associated with
Impaired Default Network
Function in Older Persons without Dementia.
Neuron 2009; 63: 178-188. PMC2738994 - O'Brien JL, O'Keefe KM, LaViolette PS, DeLuca AN,
Blacker D, Dickerson BC, Sperling RA.
Longitudinal fMRI in elderly reveals loss of hippocampal activation with
clinical decline. Neurology 2010;74(24):1969-76. - Becker JA, Hedden T, Carmasin J, Maye J, Rentz D,
Putcha D, Fischl B, Greve D, Marshall GA, Salloway S,
Marks D, Buckner RL, Sperling RA,
Johnson KA. Amyloid-beta Associated Cortical Thinning in Clinically Normal
Elderly. Annals of Neurology, in
press (available on line).
D. Research
Support
Ongoing
P01AG036694-01 Sperling (PI)
07/15/10- 6/30/15 NIH/NIA
Impact of Amyloid on the Aging Brain
The overall goals of the PPG are to elucidate the biological
significance of amyloid deposition in the aging brain and determine if
cognitively normal older individuals are on the trajectory towards prodromal
AD.
Role: Principal
Investigator; Administrative and Clinical Core Leader, PI- Project 2
R01-AG027435 and R01-AG027435-S1 Sperling (PI)
05/01/06
01/31/12 NIH/NIA
Evolution of memory-related fMRI activation
over the course of MCI and AD
The major goal of this study is to develop functional MRI
as a biomarker for clinical trials and longitudinal studies of disease
progression in MCI and AD. The goal of the supplement is to investigate
relationship of amyloid deposition to memory dysfunction in MCI.
Role: Principal Investigator
U19 AG010483 Aisen (PI)/Sperling (Project Leader)
12/13/12 - 11/30/17 NIH/NIA
Anti-Amyloid
Treatment in Asymptomatic Alzheimers Disease (The A4 Trial)
of the A4 study is to determine whether decreasing amyloid burden in clinically
normal older individuals will delay the progression of neurodegeneration and
cognitive decline.
Leader
P50 AG00513421 Hyman (PI) Sperling (PL)
4/30/2009 - 3/31/2014 NIH/NIA
Massachusetts Alzheimer's Disease Research Center Neuroimaging Program
and Project 1
The major goal of this project is to capture all ADRC related
neuroimaging in an electronic database and provide support to ADRC related
imaging projects. Project 1 goal is to
study cognitively normal older subjects participating in ADRC cohort with PiB
and MRI imaging to investigate markers of prodromal AD.
Role: Principal Investigator- Project 1; NeuroImaging Program Leader
10/1/10
9/30/15 NIH/NIA
Mentoring Imaging Research in Early AD
The overall goal of this Career Development Award is to providesupport for mentoring early investigators training in clinical and imaging
research in Alzheimers disease.
R01AG034556 (Buckner, PI)
7/1/09-6/30/14 NIH/NIA
Neural Processes Underlying Cognitive Aging
The major goal of this project is to investigate age-related
changes in fronto-parietal large scale networks
Role: Co-Investigator
R01 AG037497-01 (K. Johnson, PI)
9/1/10-8/30/15 NIH/NIA
Characterizing the Evolution of Amyloid Deposition in Normal
Elderly